229 related articles for article (PubMed ID: 28420731)
1. Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.
Kovachev PS; Banerjee D; Rangel LP; Eriksson J; Pedrote MM; Martins-Dinis MMDC; Edwards K; Cordeiro Y; Silva JL; Sanyal S
J Biol Chem; 2017 Jun; 292(22):9345-9357. PubMed ID: 28420731
[TBL] [Abstract][Full Text] [Related]
2. Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity.
Hibino E; Tenno T; Hiroaki H
Front Mol Biosci; 2022; 9():869851. PubMed ID: 35558561
[TBL] [Abstract][Full Text] [Related]
3. Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.
Pedrote MM; de Oliveira GAP; Felix AL; Mota MF; Marques MA; Soares IN; Iqbal A; Norberto DR; Gomes AMO; Gratton E; Cino EA; Silva JL
J Biol Chem; 2018 Jul; 293(29):11374-11387. PubMed ID: 29853637
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
5. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
[TBL] [Abstract][Full Text] [Related]
6. Biophysical characterization of p53 core domain aggregates.
Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
[TBL] [Abstract][Full Text] [Related]
7. Fibrillar aggregates of the tumor suppressor p53 core domain.
Ishimaru D; Andrade LR; Teixeira LS; Quesado PA; Maiolino LM; Lopez PM; Cordeiro Y; Costa LT; Heckl WM; Weissmüller G; Foguel D; Silva JL
Biochemistry; 2003 Aug; 42(30):9022-7. PubMed ID: 12885235
[TBL] [Abstract][Full Text] [Related]
8. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation.
Lei J; Cai M; Shen Y; Lin D; Deng X
Phys Chem Chem Phys; 2021 Oct; 23(40):23032-23041. PubMed ID: 34612239
[TBL] [Abstract][Full Text] [Related]
10. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the Mechanisms of R248Q Mutation-Enhanced p53 Aggregation and Its Inhibition by Resveratrol.
Liu Q; Li L; Yu Y; Wei G
J Phys Chem B; 2023 Sep; 127(36):7708-7720. PubMed ID: 37665658
[TBL] [Abstract][Full Text] [Related]
12. Reversible aggregation plays a crucial role on the folding landscape of p53 core domain.
Ishimaru D; Lima LM; Maia LF; Lopez PM; Ano Bom AP; Valente AP; Silva JL
Biophys J; 2004 Oct; 87(4):2691-700. PubMed ID: 15298872
[TBL] [Abstract][Full Text] [Related]
13. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
15. Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53.
Ghosh S; Ghosh D; Ranganathan S; Anoop A; P SK; Jha NN; Padinhateeri R; Maji SK
Biochemistry; 2014 Sep; 53(38):5995-6010. PubMed ID: 25181279
[TBL] [Abstract][Full Text] [Related]
16. p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53.
Forget KJ; Tremblay G; Roucou X
PLoS One; 2013; 8(7):e69242. PubMed ID: 23844254
[TBL] [Abstract][Full Text] [Related]
17. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
[TBL] [Abstract][Full Text] [Related]
18. Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands.
Petronilho EC; Pedrote MM; Marques MA; Passos YM; Mota MF; Jakobus B; de Sousa GDS; Pereira da Costa F; Felix AL; Ferretti GDS; Almeida FP; Cordeiro Y; Vieira TCRG; de Oliveira GAP; Silva JL
Chem Sci; 2021 Apr; 12(21):7334-7349. PubMed ID: 34163823
[TBL] [Abstract][Full Text] [Related]
19. Water Leakage Pathway Leads to Internal Hydration of the p53 Core Domain.
Lima IDM; Pedrote MM; Marques MA; Sousa GDS; Silva JL; de Oliveira GAP; Cino EA
Biochemistry; 2023 Jan; 62(1):35-43. PubMed ID: 36535020
[TBL] [Abstract][Full Text] [Related]
20. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
